The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management....

The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused by ribavirin and PEG-IFN-α2 or IFN-α combination therapy were not severe and we progressed without discontinuation of the antiviral treatment....

Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in ...

BACKGROUND The consensus therapy for chronic hepatitis C infection is based on a synergistic combination of pegylated interferon and ribavirin. The therapy leads to a sustained virological response in around 60% of infected patients. The mechanism by which this synergy occurs has not yet been elucidated. Several mechanisms of action have been proposed; one suggests that ribavirin, which is a nu...

Egypt has the highest hepatitis C virus (HCV) prevalence in the world, it has been reported that 14.7% of Egyptian population is chronically infected with HCV and 90% of them are genotype-4 (El-Zanaty et al, 2011) and (Guerra et al, 2012). Up to now, the standard of care (SOC) treatment of chronic HCV infection consists of (pegylated) interferon-Alpha and oral ribavirin. (Hendy et al, 2011). Th...

The potential exposure to ribavirin aerosol in the environment was assessed in nurses caring for infants and children with severe lower respiratory tract infections due to respiratory syncytial virus. Ribavirin aerosol was administered via a ventilator, oxygen tent, or oxygen hood. Participants worked directly with infants receiving ribavirin for 20.0 to 35.0 h over a 3-day period. No toxic or ...

We previously showed that equilibrative nucleoside transporter 1 (ENT1) is a primary ribavirin transporter in human hepatocytes. However, because the role of this transporter in the antiviral mechanism of the drug remains unclear, the present study aimed to elucidate the role of ENT1 in ribavirin antiviral action. OR6 cells, a hepatitis C virus (HCV) replication system, were used to evaluate bo...

objectives the main goal of the treatment of the hepatitis c virus (hcv) infection is reduction and elimination of viruses as well as achieving high sustained viral response (svr). the present study aimed to assess response to treatment of hcv infection by focusing on virological and biochemical aspects. methods this study was performed in hamadan, iran on hcv infected patients who were referre...

Apple hammerhead viroid (AHVd) was detected in the apple cultivar ‘Šampion’ and mixed infection with Solanum nigrum ilarvirus 1 (SnIV-1) cultivars ‘Selena’ ‘Jonagored Supra’, using a high-throughput sequencing method. Experiments were conducted to eliminate both pathogens apples meristem tip cultures combination antivirotics ribavirin, rimantadine, zidovudine. Elimination of verified by repeate...

Eid al Adha during CCHF transmission season poses a threat of exposing large population to this viral haemorrhagic fever. CCHF was first reported in Crimea in 1944. Oral ribavirin and general supportive therapy is the mainstay of treating CCHF case. Eid al Adha is a unique epidemiological event which shifts the risk of CCHF infection from high risk population to general population. During Eid, ...